AB Science Advances in AML Study With New European Approvals

AB Science SA has received regulatory approval to advance to the third stage of its Phase I/II study on the molecule AB8939 in combination with venetoclax for relapsed/refractory acute myeloid leukemia (AML). This new phase has been approved in France, Germany, Spain, and Greece. The study aims to determine the maximum tolerated dose of AB8939, a drug targeting microtubules and cancer stem cells, in combination with venetoclax, an inhibitor of BCL-2.

AB8939's dual mechanisms offer potential benefits, including reduced toxicity compared to standard chemotherapies and a synergistic effect when combined with venetoclax. Preclinical data suggest promising results, particularly for patients with TP53 mutations or complex karyotypes. The AML treatment market presents a significant opportunity, estimated at over €2 billion annually.